Wells Fargo downgraded Incyte (INCY) to Equal Weight from Overweight with a $107 price target
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte Advances Microneedle Skin Sampling Platform With Completion of Observational Study in Atopic Dermatitis
- Incyte: Transitioning Beyond Jakafi With a Promising but Unproven Late-Stage Pipeline Warrants Hold Rating
- Incyte: Post-Jakafi Revenue Gap and Execution Risks Undermine Confidence, Justifying Sell Rating
- Incyte price target raised to $128 from $101 at TD Cowen
- Balancing Near‑Term Strength and Post‑Jakafi Uncertainty: Why Incyte Merits a Hold Rating